Source-linked trial list

The registrations behind this number.

Verify the exact trial registrations behind a company, intervention, programme or topic count.

Exact trial list

12 matching trial registrations

Intervention Faricimab
Topic Vision ageing

Showing 1–12 of 12. Every record below meets all the filters shown above.

Active Not RecruitingNCT06439576

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Phase not reported · 1,000 planned enrolment

Countries listed: 1
Registry update: August 10, 2026

Verify in the registry →

Active Not RecruitingNCT06795048

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

PHASE4 · 274 planned enrolment

Countries listed: 12
Registry update: July 31, 2026

Verify in the registry →

RecruitingNCT06271330

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.

Phase not reported · 100 planned enrolment

Countries listed: 1
Registry update: June 24, 2026

Verify in the registry →

CompletedNCT07484074

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

PHASE1 · 164 planned enrolment

Countries listed: 2
Registry update: March 19, 2026

Verify in the registry →

CompletedNCT04777201

A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

PHASE3 · 1,036 planned enrolment

Countries listed: 27
Registry update: October 24, 2025

Verify in the registry →

Not Yet RecruitingNCT07088445

Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration

Phase not reported · 35 planned enrolment

Countries listed: 0
Registry update: July 28, 2025

Verify in the registry →

CompletedNCT03823287

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

PHASE3 · 671 planned enrolment

Countries listed: 15
Registry update: July 23, 2025

Verify in the registry →

CompletedNCT03823300

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

PHASE3 · 658 planned enrolment

Countries listed: 21
Registry update: July 11, 2025

Verify in the registry →

UnknownNCT06572553

Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

PHASE2 · PHASE3 · 30 planned enrolment

Countries listed: 1
Registry update: August 27, 2024

Verify in the registry →

CompletedNCT06231121

Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

Phase not reported · 13 planned enrolment

Countries listed: 1
Registry update: January 30, 2024

Verify in the registry →

CompletedNCT06124677

Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments

Phase not reported · 46 planned enrolment

Countries listed: 1
Registry update: December 11, 2023

Verify in the registry →

CompletedNCT02484690

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

PHASE2 · 273 planned enrolment

Countries listed: 1
Registry update: November 12, 2020

Verify in the registry →